Towards Allograft Longevity: Leveraging Omics Technologies to Improve Heart Transplant Outcomes.

IF 3.8 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Heart Failure Reports Pub Date : 2023-12-01 Epub Date: 2023-11-15 DOI:10.1007/s11897-023-00631-z

Lauren K Truby, Dimitri Maamari, Amit Saha, Maryjane Farr, Jawan Abdulrahim, Filio Billia, Matthias Peltz, Kiran K Khush, Thomas J Wang

{"title":"Towards Allograft Longevity: Leveraging Omics Technologies to Improve Heart Transplant Outcomes.","authors":"Lauren K Truby, Dimitri Maamari, Amit Saha, Maryjane Farr, Jawan Abdulrahim, Filio Billia, Matthias Peltz, Kiran K Khush, Thomas J Wang","doi":"10.1007/s11897-023-00631-z","DOIUrl":null,"url":null,"abstract":"Purpose of review: Heart transplantation (HT) remains the optimal therapy for patients living with end-stage heart disease. Despite recent improvements in peri-transplant management, the median survival after HT has remained relatively static, and complications of HT, including infection, rejection, and allograft dysfunction, continue to impact quality of life and long-term survival.Recent findings: Omics technologies are becoming increasingly accessible and can identify novel biomarkers for, and reveal the underlying biology of, several disease states. While some technologies, such as gene expression profiling (GEP) and donor-derived cell-free DNA (dd-cfDNA), are routinely used in the clinical care of HT recipients, a number of emerging platforms, including pharmacogenomics, proteomics, and metabolomics, hold great potential for identifying biomarkers to aid in the diagnosis and management of post-transplant complications. Omics-based assays can improve patient and allograft longevity by facilitating a personalized and precision approach to post-HT care. The following article is a contemporary review of the current and future opportunities to leverage omics technologies, including genomics, transcriptomics, proteomics, and metabolomics in the field of HT.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"493-503"},"PeriodicalIF":3.8000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Heart Failure Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11897-023-00631-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/15 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Heart transplantation (HT) remains the optimal therapy for patients living with end-stage heart disease. Despite recent improvements in peri-transplant management, the median survival after HT has remained relatively static, and complications of HT, including infection, rejection, and allograft dysfunction, continue to impact quality of life and long-term survival.

Recent findings: Omics technologies are becoming increasingly accessible and can identify novel biomarkers for, and reveal the underlying biology of, several disease states. While some technologies, such as gene expression profiling (GEP) and donor-derived cell-free DNA (dd-cfDNA), are routinely used in the clinical care of HT recipients, a number of emerging platforms, including pharmacogenomics, proteomics, and metabolomics, hold great potential for identifying biomarkers to aid in the diagnosis and management of post-transplant complications. Omics-based assays can improve patient and allograft longevity by facilitating a personalized and precision approach to post-HT care. The following article is a contemporary review of the current and future opportunities to leverage omics technologies, including genomics, transcriptomics, proteomics, and metabolomics in the field of HT.

查看原文本刊更多论文

迈向同种异体移植寿命:利用组学技术改善心脏移植结果。

回顾目的:心脏移植(HT)仍然是终末期心脏病患者的最佳治疗方法。尽管最近移植期管理有所改善，但移植后的中位生存期仍然相对稳定，而HT的并发症，包括感染、排斥反应和同种异体移植物功能障碍，继续影响生活质量和长期生存。最近的发现:组学技术正变得越来越容易获得，可以识别新的生物标志物，并揭示几种疾病状态的潜在生物学。虽然一些技术，如基因表达谱(GEP)和供体来源的无细胞DNA (dd-cfDNA)，通常用于HT受体的临床护理，但许多新兴平台，包括药物基因组学、蛋白质组学和代谢组学，在识别生物标志物以帮助移植后并发症的诊断和管理方面具有很大的潜力。基于组学的分析可以通过促进个性化和精确的ht后护理方法来改善患者和同种异体移植的寿命。下面的文章回顾了当前和未来利用组学技术的机会，包括基因组学、转录组学、蛋白质组学和代谢组学在HT领域的应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Heart Failure Reports Medicine-Emergency Medicine

CiteScore

5.30

自引率

0.00%

发文量

期刊介绍： This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of heart failure. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as investigative, pharmacologic, and nonpharmacologic therapies, pathophysiology, and prevention. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.